Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra-OTS in Severe/Critical COVID-19 with ARDS
NCT04922957Phase 2Terminated
- Sponsor
- Enlivex Therapeutics
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing ALLOCETRA-OTS with Placebo (2 arms). Primary endpoints: Time to improvement at 28 days, Support by Invasive Mechanical Ventilation (IMV) or Extracorporeal Membrane Oxygenation (ECMO) at 28 days and 1 more. Started Sep 2021; status: terminated.
02
Drugs
Allocetra
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04922957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922957.